Business
SciSparc Signs Agreement to Conduct its Clinical Trial in Autism Spectrum Disorder with Soroka Medical Center
Ethics Committee and Israeli Ministry of Health approvals already received for the Company's study with its proprietary SCI-210 treatment TEL AVIV, Israel,
About this update from Scisparc Ltd.
[{"type":"text","content":"Ethics Committee and Israeli Ministry of Health approvals already received for the Company's study with its proprietary SCI-210 treatment TEL AVIV, Israel, Jan. 09, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (\"Company\" or \"SciSparc\"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced it has signed an agreement with the Soroka University Medical Center, in Be'er-Sheva, Israel (\"Soroka Medical Center\") to conduct the Company’s clinical study for SCI-210 in patients suffering from autism spectrum disorder (\"ASD\"). During 2022, the Company received approvals from the Israeli Ministry of Health as well as the Ethics Committee of the Soroka University Medical Center, in Be'er-Sheva, Israel, to conduct the Company’s clinical trial. “The signing of the agreement with Soroka Medical Center represents another step towards commencing our clinical trial in ASD,” commented Oz Adler, SciSparc's Chief Executive Officer. \"The trial in ASD strengthens the Company's advanced clinical programs, alongside our phase IIb clinical trial for SCI-110 in patients with Tourette Syndrome and the phase IIa clinical trial of SCI-110 in patients with Alzheimer's disease and agitation. We are honored to collaborate with Soroka Medical Center, a leading medical center in Israel which co-established and is a partner of the Israeli National Centre for Autism and Neurodevelopment Research, a leading international center for innovation in translational research, diagnosis and interventions in ASD and other neurodevelopmental conditions. Soroka Medical Center is yet another example for our continuous efforts to collaborate with leading medical institutions in the world.\" The trial will investigate the effect and safety of SciSparc’s drug candidate SCI-210, a proprietary combination of cannabidiol (“CBD”) and CannAmide™, in comparison to CBD monotherapy in treating ASD. The study's objectives are to evaluate the safety, tolerability and efficacy of SCI-210 in children with ASD in a randomized, double-blind, placebo controlled with cross-over study. The design of the study includes a 20-week, randomized double-blind placebo-controlled with cross-over clinical trial of 60 children. The trial has three primary efficacy end points: the Aberrant ...